Urinary tract cancer, including urothelial carcinoma and renal cell carcinoma, are major malignant diseases worldwide. Bladder cancer is the principal malignancy of the urinary tract and the ninth most common malignancy worldwide ([@bib36]). Urothelial carcinoma is typically diagnosed in elderly individuals, with a median age of 69--71 years ([@bib30]; [@bib40]), and is associated with male sex and exogenous and environmental risk factors such as chemical carcinogens, cigarette smoking, arsenic, medications (i.e., Phenacetin, Cyclophosphamide and hiazolidinediones), *aristolochic* acid, and chronic infection/inflammation ([@bib17]; [@bib11]; [@bib37]; [@bib19]; [@bib22]; [@bib32]). In addition, cigarette smoking, hypertension, analgesics and obesity are associated with a higher risk of developing renal cell carcinoma ([@bib9]; [@bib28]). In Taiwan, the incidence of urinary tract cancer in 2009 was 23.1 and 14.5 per 100 000 person-year for men and women, respectively [@bib5].

Tuberculosis (TB), a global public health threat, is still a leading cause of death, especially in underdeveloped and developing countries ([@bib4]). Although its incidence and mortality rates have steadily declined since 1950, TB remains a leading infectious disease in Taiwan ([@bib7]; [@bib12]). It is characterised by chronic caseous granulomatous inflammation that can occur in any organ to cause tissue destruction and structural distortion ([@bib13]). Urinary TB (UTB) is a relatively common form of extra-pulmonary TB, constituting 3--5% of all TB cases ([@bib48]). If not detected or treated early, it may cause urinary tract scaring and later, obstructive uropathy and urinary tract infection or inflammation ([@bib2]). In chronic inflammation, the urinary tract mucosa is predisposed to cell dysplasia and urinary tract cancer ([@bib27]). However, the association between UTB and urinary tract cancer, including urothelial carcinoma and renal cell carcinoma, has never been investigated.

Using the National Health Insurance Research Database (NHIRD) of Taiwan, the present study analysed a nationwide cohort with a follow-up duration of 15 years to investigate the risk factors for urinary tract cancer, with an emphasis on prior UTB history.

Methods
=======

The Institutional Review Board of Buddhist Tzu Chi General Hospital, Taipei Branch, Taiwan, approved the study and waived informed consent owing to the retrospective design. Patients with TB were identified from the NHIRD. The influence of UTB and other co-morbidities on the risk of developing urinary tract cancer were studied. All selected cases were followed-up until 31 December 2010 or until the patients were either lost to follow-up (cancelled health insurance prior to 31 December 2010) or developed urinary tract cancer.

Selection criteria for active TB
--------------------------------

Active TB was defined by at least two ambulatory visits or one in-patient record with a compatible diagnosis (ICD-9-CM codes 010--018 and A-codes A020--A022, A025), prescriptions consisting of at least two anti-TB drugs simultaneously for ⩾120 days of a 180-day period, and at least one prescription consisting of three or more anti-TB drugs. The anti-TB drugs included isoniazid, rifampicin, ethambutol, pyrazinamide, prothionamide, terizidone, streptomycin, kanamycin, quinolones, cycloserine, and aminosalicylic acid. The individual anti-TB agents were converted from the claims data according to the defined daily doses and grouped according to their pharmacologic categories [@bib47]; [@bib25]). For patients with end-stage renal disease (ESRD), the prescriptions were adjusted accordingly ([@bib29]).

The index date was defined as the initial date of anti-TB treatment, which was moved forward if there were other respiratory diagnoses or orders of acid-fast smear, mycobacterial culture, bronchoscopy, pleural biopsy, or tuberculin skin test within 180 days prior to start of anti-TB treatment, as previously reported ([@bib24]). Patients with TB and an index date between 1 January 1998 and 31 December 2008 were enrolled. Those with follow-up duration \<1 year prior to the index date were excluded to ensure a sufficient observation period for identifying co-morbidities and pre-existing history of urinary tract cancer. Patients who develop urinary tract cancer within 1 year after the index date were also excluded. Urinary TB was identified by specific diagnoses (ICD-9-CM 016, 016.0--016.3, 016.9, and A-code A025).

Identifying patients with urinary tract cancer
----------------------------------------------

The urinary tract cancer was identified by compatible ICD-9-CM codes (188 and 189) or A-codes (A126 and A129) from the Registry for Catastrophic Illness Patient Database, a separate section of the NHIRD that required histologic confirmation. Patients with urinary tract cancer were further classified as having renal cell carcinoma (ICD-9-CM 189 and 189.0) or urothelial carcinoma (all other else among ICD-9-CM 188 and 189). The selection process and the incidence rates of urinary tract cancer among TB patients are shown in [Figure 1](#fig1){ref-type="fig"}.

The incidence of urinary tract cancer during the study period was also calculated in the non-TB general population from the Longitudinal Health Insurance Database 2010 (LHID 2010), a subset of the NHIRD containing the original claims data of one million beneficiaries enrolled in 2010 randomly sampled from the registry for beneficiaries. The characteristics of the LHID have been described previously ([@bib24]).

Co-morbidities and other diseases
---------------------------------

Malignancy other than urinary tract cancer, chronic obstructive pulmonary disease (COPD), ESRD, liver cirrhosis, organ transplantation, autoimmune diseases, and acquired immuno-deficiency disease were identified according to a previous publication ([@bib24]). Patients were considered as having diabetes mellitus if they had at least one hospital admission or three (or more) out-patient visits with a compatible diagnostic code (ICD-9-CM code 250 or A-code A181) within 365 calendar days. To avoid including women with gestational diabetes, diabetes visit claims within 270 days before parturition were excluded ([@bib6]). Urinary tract infections were identified by diagnostic codes (ICD-9-CM codes 590, 595, 597, and 599.0 and A-codes A351, A353, and A359) within 1 month prior to or after the index date. Obstructive uropathy was identified by compatible diagnostic codes (ICD-9-CM codes 591, 592, 594, 596, 598, 599.3, and 599.6, and A-codes A352 and A359) prior to the index date. Arsenic intoxication was identified by any ambulatory visit or in-patient records with the diagnosis code ICD-9-CM 985.1. The low income group was identified from the insurance status, and was defined as having an annual household income below 4500 US dollars [@bib38].

Statistical analysis
--------------------

Inter-group differences were compared using the independent sample *t*-test or analysis of variance for numerical variables and the *χ*^2^-square test, Fisher\'s exact test for categorical variables, or generalised estimating equations for incidence rates as appropriate. Curves of time to urothelial carcinoma and renal cell carcinoma were generated using the Kaplan--Meier method and compared using the log rank test.

The effects of UTB and other co-morbidities on the risk of developing urothelial carcinoma and renal cell carcinoma were investigated separately using the Cox proportional hazards model. Variables included sex, age, co-morbidities, and adherence to anti-TB treatment. Because tobacco use was uncommon in female Taiwanese (4%) ([@bib46]), analysis was restricted to sub-populations of female and male patients separately to explore the confounding effects of smoking. To explore the possible interaction of UTB with different age groups, sub-population analyses were also performed by dividing the TB patients into those\<60 or⩾60 years of age.

Basic model-fitting techniques, including variable selection, goodness-of-fit, adjusted generalised *R*^2^, and regression diagnostics (residual analysis, detection of influential cases, and check for multi-collinearity) were applied to ensure the quality of the multivariate analysis. Significance levels for entry and stay were set at 0.15. Statistical significance was set at a two-sided *P*\<0.05. All analyses were performed using the SAS software (SAS Institute Inc., Cary, NC, USA).

Results
=======

From a nationwide cohort of \>27 million beneficiaries, 169 810 TB cases were identified, including 136 369 with TB onset during the study period ([Figure 1](#fig1){ref-type="fig"}). Among them, 625 with \<1 year observation duration prior to TB onset and 562 patients who developed urinary tract cancer within 1 year after TB onset were excluded. The remaining 135 142 TB patients (956 936 person-years) were included for further analysis.

The mean age of the TB cases was 57.5±19.5 years, with a male--female ratio of 2.2. The mean and median durations of follow-up were 7.1±3.2 and 7.0 years, respectively. Male TB patients (mean age, 59.2±18.5 years) were older than female patients (mean age, 52.5±21.0 years). Urinary TB was diagnosed in 1287 (1.0%) ([Table 1](#tbl1){ref-type="table"}). Forty-five (3.5%) of the patients with UTB and 5368 (4.0%) of those without UTB cancelled health insurance (*P*=0.350 by the *χ*^2^-square test).

The most common underlying co-morbidities among UTB patients were obstructive uropathy, diabetes mellitus, COPD, and ESRD. Compared with patients without UTB, UTB patients were more likely to have obstructive uropathy, urinary tract infection, autoimmune disease, ESRD, and previous history of organ transplantation. Of the TB cases, 64.5% strictly adhered to and completed the standard four-combined regimen TB treatment (i.e., isoniazid, rifampicin, ethambutol, and pyrazinamide in the first 2 months, followed by isoniazid, rifampicin with or without ethambutol for the next 4 months). Another 7.4% received the standard triple chemotherapy of isoniazid, rifampicin plus ethambutol. Relapse of TB occurred in 4721 (3.5%) of the enrolled TB patients.

Urothelial carcinoma and renal cell carcinoma were diagnosed in 411 (0.4%) and 98 (0.1%) of the TB patients, corresponding to incidence rates of 43 and 10 per 100 000 person-years, respectively. In both the TB patients and the non-TB general population, the incidence of urinary tract cancer (either renal cell carcinoma or urothelial carcinoma) increased with age ([Table 2](#tbl2){ref-type="table"}). Among those aged 40--60 years, TB patients had a higher risk of developing urinary tract cancer than the non-TB population. Except for patients younger than 40 years, male patients had a higher incidence of urinary tract cancer than female patients. For female patients, the incidence of urothelial carcinoma was remarkably higher among the TB patients than among the non-TB general population across all age groups, and especially in the younger subjects. There were no differences in the incidence of renal cell carcinoma between the TB and non-TB subjects in both male and female patients.

The mean interval between the index date of TB and the diagnosis of urinary tract cancer was 4.7±2.8 years. The most common site of urinary tract cancer involvement was the bladder (69%), followed by the kidneys (19%), renal pelvis (6%), ureter (6%), and urethra (1%). Patients with UTB were older and had significantly higher risk of developing urothelial carcinoma than those without UTB (1.3% *vs* 0.4%, *P*\<0.001, by *χ*^2^-square test) ([Table 1](#tbl1){ref-type="table"}). The curves of time to development of urothelial carcinoma in patients with and without UTB were significantly different by the log rank test ([Figure 2](#fig2){ref-type="fig"}). The curves of time to the development of renal cell carcinoma overlapped for the patients with and without UTB ([Figure 3](#fig3){ref-type="fig"}).

Among all TB patients enrolled, the clinical characteristics for those who developed urothelial carcinoma, renal cell carcinoma and those without subsequent urinary malignancy are summarised in [Table 3](#tbl3){ref-type="table"}. The mean interval from the index date of TB to the diagnosis of urothelial carcinoma and renal cell carcinoma were 4.6±2.7 and 5.1±3.1 years, respectively.

Cox proportional hazards model analysis of all the variables listed in [Table 1](#tbl1){ref-type="table"} for the 135 142 TB cases revealed that UTB was an independent risk factor for urothelial carcinoma (hazard ratio 3.38 (95% confidence interval, 2.01--5.69)) ([Table 4](#tbl4){ref-type="table"}). Moreover, age, male sex, ESRD, obstructive uropathy, organ transplantation and arsenic intoxication significantly increased the risk of developing urothelial carcinoma. Age, male sex, ESRD and obstructive uropathy were independent risk factors for developing renal cell carcinoma. However, UTB was not associated with the development of renal cell carcinoma ([Table 5](#tbl5){ref-type="table"}). In sub-population analysis of male and female patients separately, urinary TB remained an independent risk factor for developing urothelial carcinoma in both sexes, but the magnitude of association was higher among female patients than among male patients or the overall TB population ([Table 6](#tbl6){ref-type="table"}). For sub-population analyses of younger and older (⩾60 years) patients, UTB was also independently associated with the development of urothelial carcinoma in both age groups, but the hazards ratio of UTB was higher in younger patients.

Discussion
==========

Using a nationwide cohort, the present study clearly demonstrates that urinary TB involvement is an important risk factor for developing urothelial carcinoma, especially among younger female patients. The strong association remains valid even after adjusting for other independent risk factors such as age, sex, ESRD, obstructive uropathy, history of organ transplantation, and arsenic intoxication. Nonetheless, regardless of whether TB involved the urinary tract had no significant impact on the risk of developing renal cell carcinoma.

The urinary tract, especially the collecting system, is one of the most common sites of extra-pulmonary TB involvement ([@bib48]). Unlike intra-vesical immunotherapy for urinary tract cancer with *Bacillus* Calmette--Guerin (BCG), which, after being internalised and processed by antigen-presenting cells and urothelial tumour cells, acts like killer cell targets to induce short-term inflammation ([@bib3]; [@bib33]), TB is characterised of chronic caseous granulomatous inflammation that can cause devastating tissue damage if left untreated ([@bib13]). Delay in TB diagnosis may vary from 3 to 6 months ([@bib23]; [@bib42]; [@bib24]). Diagnosing extra-pulmonary TB may even be more challenging. Delays in TB diagnosis and in the initiation of anti-TB treatment may increase the duration and severity of urinary tract inflammation and organ fibrosis, thus making the patient more vulnerable to urinary tract cancer. Furthermore, after the completion of anti-TB treatment, tissue scaring can still predispose to obstructive uropathy and subsequent urinary tract infection/inflammation ([@bib2]), which predispose to cell dysplasia and ongoing cancer formation ([@bib20]; [@bib10]; [@bib27]). During the chronic irritation phase, inflammatory cells like macrophages may also release some lymphangiopoietic vascular endothelial growth factors that may have a novel role in peri-tumoral lymphangiogenesis and subsequent dissemination of human cancer that predispose to dismal outcomes ([@bib39]).

Cox regression analyses restricted to those aged \<60 and aged ⩾60 years separately demonstrated that UTB had a higher impact on the risk of urothelial carcinoma among younger patients. Sub-population analyses focused on each sex separately show that the risk for urinary tract cancer attributed to UTB is even higher among female patients. The baseline incidence of urothelial carcinoma was lower in the female patients compared with the male patients. The prevalence of smoking, a strong risk factor for urinary tract cancer, is also much lower among female patients than among male patients in Taiwan ([@bib46]). Thus, UTB may act as the sole contributor to carcinogenesis among young female patients who are free of other risk factors for urothelial carcinoma. Furthermore, for patients with bladder cancer, female patients are associated with worse outcome than male patients, probably because female patients are more likely to have aggressive histology at initial presentation ([@bib34]; [@bib18]; [@bib35]). Thus, it is imperative that UTB patients, especially young female patients, be followed-up carefully in the post-treatment period for subsequent urothelial carcinoma.

Cigarette smoking is the most important attributable risk for urothelial cancer and bladder cancer in Western countries ([@bib17]), with over 60 known carcinogenic compounds in cigarette smoke ([@bib14]). In addition, cigarette smoking also increases the susceptibility to TB ([@bib26]). Because smoking status is not available in the NHIRD, it is possible that some of the effects of UTB and male sex on the development of urothelial carcinoma observed in the present study were through the effects of cigarette smoking. However, in the sub-population analyses restricted to female and male patients separately, urinary TB remained an independent risk factor for urothelial carcinoma among the female patients, the predominantly non-smoking population ([@bib46]), with a hazard ratio higher than that of male patients and the overall TB population. Hence, although the final Cox regression model in the present study was not adjusted for cigarette smoking, the effect of UTB on the risk of urothelial carcinoma should not be completely attributed to the confounding effect of cigarette smoking.

Except for UTB, risk factors of urothelial carcinoma disclosed in the present study, such as age, male sex, ESRD, obstructive uropathy, arsenic intoxication, and organ transplantation, are consistent with previous reports. In southern Taiwan, water with arsenic acid contamination is a known risk factor for several diseases, including urothelial carcinoma and blackfoot disease, a peripheral vascular disease ([@bib43]; [@bib17]). Typically, urinary tract cancers are diagnosed in the elderly, predominantly those in the sixth to eighth decade, according to the National Cancer Institute\'s Surveillance ([@bib15]). Incidence increases with age and is two to three times higher in men than in women of the same age ([@bib40]; [@bib41]). In Taiwan, although the total incidence is not as high as that in western countries, the percentage of female patients is higher than in western countries, especially in the upper urinary tract malignancy group ([@bib8]). However, the present study reveals that 80.2% of TB patients with urinary tract cancer are male. The ratio of male patients is much higher than that of the general population in Taiwan and even higher than that in western countries. As both age and male sex are risk factors for urinary tract cancer in TB patients, the exceptional male predominance in patients with urinary tract cancer in the present study is probably due to the male predominance and the advanced age of men than women among the enrolled TB patients.

In our results, organ transplantation was associated with a high risk of developing urothelial carcinoma. According to previous reports, *de novo* carcinoma in the transplantation recipients may be 10 times greater than in the general population ([@bib45]). BK polyomavirus reactivation resulting from the use of immunosuppressant agents after transplantation is not uncommon. Such infections have been reported to cause aggressive urinary bladder urothelial carcinomas with adenocarcinomatous or micropapillary differentiation ([@bib1]).

Patients with ESRD are reported to have a high incidence (520 per 100 000 person-year) of developing renal cell carcinoma ([@bib16]) and higher mortality rate. Impaired function of antioxidant defence, relative immune-compromised status, and the accumulation of carcinogenic compounds due to renal dysfunction may result in increased prevalence and contribute to carcinogenesis ([@bib44]). For patients with ESRD, higher risks of cancers of the kidneys (3.60 (3.45--3.76)), bladder (1.50 (1.42--1.57)), and thyroid and other endocrine organs (2.28 (2.03--2.54)) have been observed ([@bib31]). In the present study, part of the hazard of ESRD on urinary tract cancer may be attributed to the widespread use of *Aristolochia* herbal remedies in Taiwan. The *Aristolochia* acts as a common confounding factor for ESRD and urothelial carcinoma ([@bib21], [@bib22]). Thus, keeping a high suspicion of urinary tract cancer and performing ultrasonography of the kidneys and urinary tract, urine cytology, and endoscopy if indicated are important for ESRD patients, especially for those with a history of UTB.

The present study has some limitations. Mycobacterial findings are unavailable so uncertainty in the diagnosis of TB is inevitable. By applying a very strict definition for TB, the impact of UTB is likely to be underestimated because patients who have been excluded owing to poor adherence to anti-TB treatment are prone to more severe tissue scaring, ongoing chronic inflammation, and subsequent development of urinary tract cancer. Second, because the ICD-9-CM codes cannot differentiate among histologic types of urinary tract cancer (i.e., renal cell carcinoma, adenocarcinoma, and small cell carcinoma), the specific effects of UTB on individual histologic type of urinary tract cancer cannot be evaluated. Third, the interpretation of the causal relationship between UTB and urothelial carcinoma based on their temporality is difficult because there could be a delay in the diagnosis of either condition. Finally, the effects of socio-economic status and education level, which may confound both the occurrence of TB and urinary tract cancer development, cannot be reliably evaluated from the NHIRD.

Conclusions
===========

Urinary TB poses a high risk of developing urothelial carcinoma even after adjusting for other known risk factors such as age, sex, ESRD, obstructive uropathy, and arsenic intoxication. In TB endemic areas, the urinary tract of TB patients should be examined closely. Patients with urinary TB, especially for younger female patients, should be followed-up carefully in the post-treatment period. Ultrasonography of the kidneys and urinary tract, urine cytology, or endoscopy should also be an integral part of follow-up examinations. The distressing finding of subsequent urinary tract cancer dictates the need for early suspicion and intervention.
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###### Clinical characteristics of tuberculosis patients with and without urinary involvement (*n*=135 142)

                                                                        **Yes**         **No**       
  ------------------------------------------------------------------ ------------- ---------------- ------------------------------------
  Age (year)                                                           58.9±16.7      57.1±19.6     \<0.001[a](#t1-fn2){ref-type="fn"}
  Male                                                                820 (63.7%)   92 069 (68.8%)  \<0.001[b](#t1-fn3){ref-type="fn"}
  Developing urinary tract cancer                                      17 (1.3%)      492 (0.4%)    \<0.001[b](#t1-fn3){ref-type="fn"}
   Renal cell carcinoma                                                2 (0.2%)       96 (0.1%)     0.240[c](#t1-fn4){ref-type="fn"}
   Urothelial carcinoma                                                15 (1.2%)      396 (0.3%)    \<0.001[b](#t1-fn3){ref-type="fn"}
  Follow-up duration (year)                                             7.2±3.3        7.1±3.2      0.182[a](#t1-fn2){ref-type="fn"}
  Cancelled health insurance                                           45 (3.5%)     5368 (4.0%)    0.350[b](#t1-fn3){ref-type="fn"}
  Diabetes mellitus                                                   275 (21.4%)   30 209 (22.6%)  0.305[b](#t1-fn3){ref-type="fn"}
  Obstructive uropathy                                                571 (44.4%)   18 499 (13.8%)  \<0.001[b](#t1-fn3){ref-type="fn"}
  Urinary tract infection                                             582 (45.2%)    8187 (6.1%)    \<0.001[b](#t1-fn3){ref-type="fn"}
  COPD                                                                125 (9.7%)    19 111 (14.3)   \<0.001[b](#t1-fn3){ref-type="fn"}
  Malignancy                                                           28 (2.2%)     4643 (3.5%)    0.011[b](#t1-fn3){ref-type="fn"}
  ESRD                                                                 32 (2.5%)     1527 (1.1%)    \<0.001[b](#t1-fn3){ref-type="fn"}
  Autoimmune disease                                                   16 (1.2%)      971 (0.7%)    0.030[b](#t1-fn3){ref-type="fn"}
  Liver cirrhosis                                                      5 (0.4%)       269 (0.2%)    0.195[c](#t1-fn4){ref-type="fn"}
  Transplantation                                                      7 (0.5%)       118 (0.1%)    \<0.001[c](#t1-fn4){ref-type="fn"}
  Acquired immuno-deficiency syndrome                                  3 (0.2%)       192 (0.1%)    0.439[c](#t1-fn4){ref-type="fn"}
  Arsenic intoxication                                                 1 (0.1%)       26 (0.0%)     0.228[c](#t1-fn4){ref-type="fn"}
  Low-income status                                                    27 (2.1%)     3954 (3.0%)    0.071[b](#t1-fn3){ref-type="fn"}
  **No. of days in first 2 months of anti-tuberculosis treatment**                                  
   Receiving no  anti-tuberculosis agents                               4.5±7.8        3.5±7.0      \<0.001[a](#t1-fn2){ref-type="fn"}
   Receiving ⩾3  anti-tuberculosis agents                              45.1±14.5      48.6±12.6     \<0.001[a](#t1-fn2){ref-type="fn"}
  Complete treatment with standard anti-tuberculosis regimen          879 (68.3%)   96 209 (71.9%)  0.005[b](#t1-fn3){ref-type="fn"}

Abbreviations: COPD=chronic obstructive pulmonary disease; ESRD=end-stage renal disease.

Calculated by independent-sample Student\'s *t*-test.

Calculated by *χ*^2^-square test.

Calculated by Fisher\'s exact test.

Data were either number (%) or mean±s.d.

###### Incidence of urinary tract cancer (per 100 000 person-year) in patients with TB and in the general population without TB

                           **Male**   **Female**                        
  ----------------------- ---------- ------------ ------- ------ ------ ---------
  \<40 years                 1.0         1.4       0.807   4.6    0.8   0.001
   Renal cell carcinoma      1.0         0.7       0.678   1.1    0.5   0.452
   Urothelial carcinoma       0          0.7               3.4    0.3   \<0.001
  40--60 years               26.8        19.1      0.026   14.7   7.9   0.105
   Renal cell carcinoma      10.6        7.6       0.126   1.1    2.9   0.396
   Urothelial carcinoma      16.2        11.5      0.104   13.6   5.0   0.002
  ⩾60 years                  94.1        99.6      0.446   63.9   54.4  0.138
   Renal cell carcinoma      15.9        19.0      0.296   12.1   18.7  0.143
   Urothelial carcinoma      78.2        80.6      0.721   51.8   35.7  0.014

Abbreviation: TB=tuberculosis.

*P*-value calculated with generalised estimating equations.

###### Clinical characteristics of tuberculosis patients with and without urinary tract cancer (*n*=135 142)

  **Developing urinary tract cancer**                                 **Urothelial carcinoma** ***n*****=411**   **Renal cell carcinoma** ***n*****=98**   **No** ***n*****=134 633**  ***P-*****value**
  ------------------------------------------------------------------ ------------------------------------------ ----------------------------------------- ---------------------------- ------------------------------------
  Age (year)                                                                         69.8±10.6                                  64.7±12.6                          57.1±19.6           \<0.001[a](#t3-fn2){ref-type="fn"}
  Male                                                                              327 (79.6%)                                81 (82.7%)                        92 481 (68.7%)        \<0.001[b](#t3-fn3){ref-type="fn"}
  Urinary tuberculosis                                                               15 (3.6%)                                  2 (2.0%)                          1270 (0.9%)          \<0.001[b](#t3-fn3){ref-type="fn"}
  Follow-up duration (year)                                                           4.6±2.7                                    5.1±3.1                            7.1±3.2            \<0.001[a](#t3-fn2){ref-type="fn"}
  Diabetes mellitus                                                                 116 (28.2%)                                29 (29.6%)                        30 339 (22.5%)        0.006[b](#t3-fn3){ref-type="fn"}
  Obstructive uropathy                                                               92 (22.4%)                                23 (23.5%)                        18 955 (14.1%)        \<0.001[b](#t3-fn3){ref-type="fn"}
  Urinary tract infection                                                            41 (10.0%)                                 9 (9.2%)                          8719 (6.5%)          0.002[b](#t3-fn3){ref-type="fn"}
  COPD                                                                               83 (20.2%)                                15 (15.3%)                        19 138 (14.2%)        0.002[b](#t3-fn3){ref-type="fn"}
  Malignancy                                                                         17 (4.1%)                                  4 (4.1%)                          4650 (3.5%)          0.709[b](#t3-fn3){ref-type="fn"}
  End-stage renal disease                                                            29 (7.1%)                                  6 (6.1%)                          1524 (1.1%)          \<0.001[b](#t3-fn3){ref-type="fn"}
  Autoimmune disease                                                                  4 (1.0%)                                      0                              983 (0.7%)          0.590[b](#t3-fn3){ref-type="fn"}
  Liver cirrhosis                                                                     1 (0.2%)                                      0                              273 (0.2%)          0.890[b](#t3-fn3){ref-type="fn"}
  Organ transplantation                                                               3 (0.7%)                                      0                              122 (0.1%)          \<0.001[b](#t3-fn3){ref-type="fn"}
  Acquired immuno-deficiency syndrome                                                    0                                          0                              195 (0.2%)          0.691[b](#t3-fn3){ref-type="fn"}
  Arsenic intoxication                                                                1 (0.2%)                                      0                              26 (0.0%)           0.006[b](#t3-fn3){ref-type="fn"}
  **No. of days in first 2 months of anti-tuberculosis treatment**                                                                                                                     
   Receiving no anti-tuberculosis agents                                              3.7±7.0                                    3.0±6.0                            3.5±7.0            0.672[a](#t3-fn2){ref-type="fn"}
   Receiving ⩾3 anti-tuberculosis agents                                             47.5±13.7                                  46.2±14.5                          48.6±12.6           0.034[a](#t3-fn2){ref-type="fn"}
  Complete treatment with standard regimen                                          284 (69.1%)                                62 (63.3%)                        96 742 (71.9%)        0.078[b](#t3-fn3){ref-type="fn"}

Abbreviation: COPD=chronic obstructive pulmonary disease.

Calculated by independent-sample Student\'s *t*-test

Calculated by *χ*^2^-square test.

Data were either number (%) or mean±s.d.

###### Cox regression analysis of factors possibly associated with the development of urothelial carcinoma among patients with tuberculosis

                                        ***P*****-value**   **Hazard ratio (95% confidence interval)**
  ------------------------------------- ------------------- --------------------------------------------
  Age (per year increment)              \<0.001             1.05 (1.04--1.06)
  Male                                  \<0.001             1.55 (1.22--1.98)
  End-stage renal disease               \<0.001             7.16 (4.81--10.63)
  Arsenic intoxication                  0.024               9.54 (1.34--67.96)
  Urinary involvement of tuberculosis   \<0.001             3.38 (2.01--5.69)
  Obstructive uropathy                  0.024               1.31 (1.04--1.66)
  Organ transplantation                 0.020               4.06 (1.25--13.27)

###### Cox regression analysis of factors possibly associated with the development of renal cell carcinoma among patients with tuberculosis

                             ***P*****-value**   **Hazard ratio (95% confidence interval)**
  -------------------------- ------------------- --------------------------------------------
  Age (per year increment)   \<0.001             1.02 (1.01--1.04)
  Male                       0.008               2.05 (1.21--3.48)
  End-stage renal disease    \<0.001             6.57 (2.85--15.14)
  Obstructive uropathy       0.020               1.65 (1.08--2.52)

###### Sub-population analysis by sex and age groups for the impact of urinary tuberculosis on developing urothelial carcinoma

  **Study population**   ***P*****-value**   **Hazard ratio (95% confidence interval)**
  ---------------------- ------------------- --------------------------------------------
  All                    \<0.001             3.38 (2.01--5.69)
  Male                   \<0.001             2.96 (1.57--5.60)
  Female                 \<0.001             5.26 (2.12--13.06)
  Age \<60 years         \<0.001             6.41 (2.56--16.09)
  Age ⩾60 years          0.001               2.86 (1.52--5.38)
